HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights
Pharmaceuticals Inc. at 844-627-4687 or FDA at 1-800-FDA-1088 Advise the patient to read the FDA-approved patient labeling (Medication Guide and ...
Reference ID: 4197746
888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The following important adverse reactions are described elsewhere in the labeling:.
______ HIGHLIGHTS OF PRESCRIBING INFORMATION These
at 1-844-IMMUNO1 (1-844-466-8661) or FDA at 1-800-FDA-1088 or serious adverse reactions are discussed in greater detail in other sections of the label:.
ELIQUIS (apixaban) label
See FDA-approved patient labeling (Medication Guide). Advise patients of the following: • They should not discontinue ELIQUIS without talking to their
XELJANZ (tofacitinib)
Advise the patient to read the FDA-approved patient labeling (Medication Guide). Serious Infections. Inform patients that XELJANZ/XELJANZ XR may lower the
XTANDI (enzalutamide) capsules
See 17 for PATIENT COUNSELING INFORMATION and FDA- approved patient labeling. Revised: 7/2018. FULL PRESCRIBING INFORMATION: CONTENTS*.
VICTRELIS (boceprevir) Label - FDA
in another section of the labeling: Anemia and neutropenia [see Warnings and with chronic hepatitis C in one Phase 2 open-label trial and two Phase 3
HERCEPTIN (trastuzumab) Label
Assessment of HER2 protein overexpression and HER2 gene amplification in metastatic gastric cancer should be performed using FDA-approved tests specifically for
VERZENIO® (abemaciclib) tablets for oral use
Oct 2 2021 FDA-approved patient labeling. Revised: 10/2021. FULL PRESCRIBING INFORMATION: CONTENTS*. 1. INDICATIONS AND USAGE. 1.1 Early Breast Cancer.
Tegretol - carbamazepine USP Chewable Tablets of 100 mg
018281s048lbl.pdf
